A. Sinclair Dunlop, Director at Apellis Pharmaceuticals, Inc. (APLS), sold 40,530 shares at $50.04 ($2.0M) on 2020-12-04, disclosed to the SEC on 2020-12-07.
Open-market sale of $2.0M APLS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.04 | 5,052 | $253K | 12.4% |
| 2 | $50.04 | 5,052 | $253K | 12.4% |
| 3 | $51.05 | 1,384 | $71K | 3.5% |
| 4 | $51.05 | 1,384 | $71K | 3.5% |
| 5 | $50.41 | 9,094 | $458K | 22.4% |
| 6 | $50.41 | 9,094 |
| $458K |
| 22.4% |
| 7 | $51.00 | 9,470 | $483K | 23.6% |
| Total | $50.50 avg | 40,530 | $2.0M | 100% |
| Filing → |
| APLS | SELL | 2025-09-19 | $1.4M | — | Filing → |
| APLS | SELL | 2024-09-17 | $2.7M | — | Filing → |
| APLS | SELL | 2024-06-21 | $2.9M | — | Filing → |